AI model to predict hidden lymph node cancer in lung patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This nationwide, multicenter observational study aims to develop and validate an artificial intelligence (AI) model designed to detect occult lymph node metastasis in patients with early-stage non-small cell lung cancer (NSCLC). The study addresses the challenge of undetected lymph node metastasis, which affects treatment decisions in a significant percentage of cases. By utilizing deep learning techniques to analyze imaging features alongside clinical data, the study seeks to enhance clinical decision-making and improve patient outcomes. Insights gained may also reveal biological mechanisms underlying lymph node metastasis in NSCLC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically confirmed non-small cell lung cancer;
* Clinical stage I (AJCC, 8th edition, 2017);
* Age≥18 years old;
* KPS score≥70;
* Patients who have undergone primary NSCLC radical surgery or SBRT treatment;
* Complete systemic lesion imaging assessment before primary NSCLC radical surgery or SBRT treatment (Note: Tumor size ≥ 3 cm or centrally located tumor requires PET/CT and/or invasive mediastinal staging);
* Patients willing to cooperate with the follow-up after primary NSCLC radical surgery;
* informed consent of the patient.

Exclusion Criteria:

* Poor quality of computed tomography imaging;
* Baseline imaging shows pure ground-glass nodules (GGO);
* Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.;
* Loss to follow-up.

Where it's running

• Fudan university Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Zhengfei Zhu, PhD
• Email: fuscczzf@163.com
• Phone: +86-18017312901

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating KQB365 for treating advanced solid tumors

  This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 11 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 10 other locations · NCT06720987

• AI-assisted whole-course management for safe medicine use in advanced solid tumors

  A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.

  Recruiting at 2 sites Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT07917351

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Icotinib after surgery for early EGFR-mutant NSCLC

  This study tests whether giving icotinib after surgery helps patients with early-stage EGFR-mutant NSCLC compare to just following them after surgery.

  Recruiting at 2 sites Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07806604

• AI-assisted and traditional workflows for admission diagnosis and management planning

  This trial tests whether an AI-agent workflow helps doctors make better admission diagnoses and care plans on simulated cases, compared with plain AI-assisted and traditional workflows.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07760051

• Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC

  This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Guangzhou, Guangdong and 4 other locations · NCT07754812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.